Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorSelçuk, Mahmut
dc.contributor.authorSelçuk, Eda
dc.date.accessioned2022-08-26T08:29:39Z
dc.date.available2022-08-26T08:29:39Z
dc.date.issued2021en_US
dc.identifier.issn0271-0749 - 1533-712X
dc.identifier.urihttps://doi.org/10.1097/JCP.0000000000001425
dc.identifier.urihttps://hdl.handle.net/20.500.12462/12478
dc.descriptionSelçuk, Eda (Balikesir Author)en_US
dc.description.abstractSelective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs) are antidepressants that are widely used for many psychiatric conditions, including generalized anxiety disorder, depression, panic disorder, and obsessive compulsive disorders.1–3 Venlafaxine is an SNRI with a dual mechanism of action on both serotonin (5-HT) and (at higher doses) norepinephrine (NE) pumps.4,5 Furthermore, it acts as a dual 5-HT and NE reuptake inhibitor, especially at doses of 225 mg/d or more.6 The adverse effects of venlafaxine at 75 mg/d are similar to an SSRI (ie, vomiting, weight gain nausea, sleep and gastrointestinal disturbances, and sexual dysfunction). However, at higher doses, its effects are similar to those of an NE uptake inhibitor (ie, dry mouth, tachycardia, and hypertension).4,7en_US
dc.language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.isversionof10.1097/JCP.0000000000001425en_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectPharmacology & Pharmacyen_US
dc.subjectPsychiatryen_US
dc.titleA case of unexpected ecchymosis associated with a high dose of venlafaxineen_US
dc.typeletteren_US
dc.relation.journalJournal of Clinical Psychopharmacologyen_US
dc.contributor.departmentTıp Fakültesien_US
dc.identifier.volume41en_US
dc.identifier.issue4en_US
dc.identifier.startpage496en_US
dc.identifier.endpage498en_US
dc.relation.publicationcategoryDiğeren_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster